top of page

Our Development Pipeline


Topical Minocycline, 1%

BPX-04 (topical minocycline, 1%) is being developed for the treatment of moderate-to-severe papulopustular rosacea. In a Phase 2b study, BPX-04 was shown to be well tolerated and demonstrated efficacy in reducing the number of facial inflammatory lesions among patients. BPX-04 is a topical gel formulation of fully solubilized minocycline.

Timber Pipeline 08-10-20.png

If you are interested in any of Timber’s ongoing clinical research programs, please contact

bottom of page